Importance Immune checkpoint inhibitor–induced interstitial lung disease (ICI-ILD) is
clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been …

Background Osimertinib has demonstrated impressive efficacy as a first-line treatment for
patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung …

Interstitial lung abnormality (ILA) is defined as an interstitial change detected incidentally on
CT images. It is seen in 4%–9% of smokers and 2%–7% of nonsmokers. ILA has a tendency …

Background Limited data are available on the safety and efficacy of immune checkpoint
inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD). Methods …

Immunotherapy has transformed lung cancer care in recent years. In addition to providing
durable responses and prolonged survival outcomes for a subset of patients with heavily …

Background Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory
diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy …

Abstract Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …

Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at
increased risk of developing lung cancer. Management of lung cancer in patients with ILD is …

Background Interstitial lung abnormalities (ILAs) are associated with the risk of lung cancer
and its mortality. However, the impact of ILA on treatment-related complications and survival …

In recent years, immunotherapy has been widely used to treat patients with malignant
tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of …